Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Neurogene Inc.NGNE · Entity 5160 | Director | June 12, 2025 | June 13, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Neurogene Inc.
Report date June 12, 2025 · Filed June 13, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.40 · Expires 2035-06-12 | Direct | 12,050 |
Reported balance
After 2025-06-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-06-12 · Grant · Acquired 12,050 · Balance 12,050 F1: The option vests as to 1/12 of the total shares monthly beginning July 12, 2025 until the option is fully vested on June 12, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests as to 1/12 of the total shares monthly beginning July 12, 2025 until the option is fully vested on June 12, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 12, 2025 Filed Jun 13, 2025 16:07 UTC | Neurogene Inc. NGNE · Entity 5160 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 12,050 | $0.00 Strike: $20.40 | $0.00 |
DisclosureSEC source: 0001404644-25-000067 · wk-form4_1749830826.xml · derivative · entry 1 Woods Robert Keith · CIK 0001995131 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,050 Underlying: Common Stock · 12,050 shares Expires 2035-06-12 F1 · derivative.exercise_date: The option vests as to 1/12 of the total shares monthly beginning July 12, 2025 until the option is fully vested on June 12, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| June 14, 2024 Filed Jun 17, 2024 18:37 UTC | Neurogene Inc. NGNE · Entity 5160 | GrantStock Option (Right to Buy) · Derivative | 7,700 | $0.00 Strike: $42.59 | $0.00 |
DisclosureSEC source: 0001404644-24-000071 · wk-form4_1718649445.xml · derivative · entry 1 Woods Robert Keith · CIK 0001995131 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,700 Underlying: Common Stock · 7,700 shares Expires 2034-06-14 F1 · derivative.exercise_date: This option represents a right to purchase 7,700 shares of the Issuer's common stock, which will vest in its entirety on the earlier of (a) the first anniversary of the date of grant or (b) the date of the Issuer's 2025 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through such applicable vesting date. Read SEC document |
| January 16, 2024 Filed Jan 19, 2024 00:01 UTC | Neurogene Inc. NGNE · Entity 5160 | GrantStock Option (Right to Buy) · Derivative | 15,400 | $0.00 Strike: $32.30 | $0.00 |
DisclosureSEC source: 0000950170-24-005541 · ownership.xml · derivative · entry 1 Woods Robert Keith · CIK 0001995131 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,400 Underlying: Common Stock · 15,400 shares Expires 2034-01-16 F1 · derivative.exercise_date: This option represents the right to purchase 15,400 shares of common stock of the Issuer, and vests in equal monthly installments through January 16, 2027, subject to the reporting person's continued service to the Issuer through each applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.